Voquezna generic alternative?

Is there a generic version of Voquezna?
No. Voquezna (vosoritide) is a biologic drug approved in 2024 for achondroplasia, and no generic has entered the market.

What does “generic” mean for a biologic like Voquezna?
Biologic generics are called biosimilars. They must demonstrate that they are highly similar to the reference product in quality, safety, and efficacy. The regulatory pathway is lengthy and expensive, so biosimilars typically appear many years after the original approval.

When could a generic or biosimilar appear?
The FDA grants 12 years of exclusivity to biologics starting from approval. That would place potential biosimilar entry around 2036, assuming patents and exclusivity periods have not expired earlier.

Who owns the key patents for Voquezna?
Horizon Therapeutics and its partner hold multiple patents covering the C‑type natriuretic peptide (CNP) analog used in Voquezna, its manufacturing process, and its formulation. Current patent listings show expiry dates ranging from 2029 to 2037, so exclusivity remains in force for several more years.
[1]

Could other companies develop a biosimilar before patent expiry?
They could file for approval after the earliest patent lapses, but they must also overcome the 12‑year exclusivity. Even then, they face legal challenges and the need for extensive clinical testing.

What is Voquezna’s mechanism of action?
Vosoritide mimics CNP, stimulating growth in the long bone growth plates by activating the natriuretic peptide receptor‑B. This promotes linear bone growth in children with achondroplasia.

Are there any other approved treatments for achondroplasia?
Currently, no other drug is FDA‑approved for achondroplasia. Growth hormone therapy has been studied but lacks FDA approval.

What about the cost of Voquezna?
Because it is the sole therapy, pricing is set by Horizon Therapeutics. Insurance coverage varies, and patients may need prior authorization.

Are any biosimilar trials underway?
There are no announced trials for a Voquezna biosimilar at this time.

Can patients consider off‑label or alternative therapies?
No off‑label use of Voquezna exists, and no alternative biologics are approved for this indication.

Where can I find more detailed patent information?
DrugPatentWatch.com lists the specific patents, filing dates, and expiration information for Voquezna.

Sources
[1] https://www.drugpatentwatch.com